Homology Medicines (NASDAQ: FIXX)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-11 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.350 | -0.680 | -0.3300 | ||||
REV | 802.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Homology Medicines (NASDAQ: FIXX) through any online brokerage.
Other companies in Homology Medicines’s space includes: 89bio (NASDAQ:ETNB), OncoCyte (NASDAQ:OCX), Ambrx Biopharma (NYSE:AMAM), TCR2 Therapeutics (NASDAQ:TCRR) and Fusion Pharmaceuticals (NASDAQ:FUSN).
The latest price target for Homology Medicines (NASDAQ: FIXX) was reported by Credit Suisse on Tuesday, May 17, 2022. The analyst firm set a price target for 2.10 expecting FIXX to rise to within 12 months (a possible 6.60% upside). 10 analyst firms have reported ratings in the last year.
The stock price for Homology Medicines (NASDAQ: FIXX) is $1.97 last updated July 6, 2022, 8:00 PM UTC.
There are no upcoming dividends for Homology Medicines.
Homology Medicines’s Q2 earnings are confirmed for Thursday, August 11, 2022.
There is no upcoming split for Homology Medicines.
Homology Medicines is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.